Lista de obras -

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

artículo científico publicado en 2013

An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when

scholarly article by Jo Caers et al published 31 August 2018 in Haematologica

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

artículo científico publicado en 2014

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

artículo científico publicado en 2005

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

scientific article published on 05 February 2014

CD3‐induced T‐cell activation in the bone marrow of myeloma patients: major role of CD4+ cells ⬇️

artículo científico publicado el 1 de julio de 1995

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

scientific article published on 22 August 2019

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

scientific article published on 14 April 2020

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

artículo científico publicado en 2011

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.

artículo científico publicado en 2015

Current multiple myeloma treatment strategies with novel agents: a European perspective

scientific article published on 19 January 2010

Dual rearrangement of immunoglobulin and T-cell receptor gene in a case of T-cell hairy-cell leukemia ⬇️

artículo científico publicado el 1 de febrero de 1991

Early disappearance of murine plasmocytoma stem cells in long-term bone marrow culture

artículo científico publicado el 1 de agosto de 1992

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

artículo científico publicado en 2014

European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.

artículo científico publicado en 2010

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

artículo científico publicado en 2018

European perspective on multiple myeloma treatment strategies in 2014

artículo científico publicado en 2014

European perspective on multiple myeloma treatment strategies: update following recent congresses

artículo científico publicado en 2012

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

scientific article published on 09 August 2007

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

artículo científico publicado en 2018

How to manage neutropenia in multiple myeloma

artículo científico

Insights on Multiple Myeloma Treatment Strategies

artículo científico publicado en 2018

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

artículo científico publicado en 2011

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

artículo científico publicado en 2016

Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma

artículo científico publicado en 2010

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

artículo científico publicado en 2018

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

scientific article published on 22 May 2020

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

artículo científico publicado en 2010

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Multiple independent immunoglobulin class-switch recombinations occurring within the same clone in myeloma

artículo científico publicado el 1 de diciembre de 1992

Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.

artículo científico publicado en 2011

Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents

artículo científico publicado en 2015

Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids

artículo científico publicado el 1 de agosto de 1992

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

artículo científico publicado en 2008

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

artículo científico publicado en 2011

Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias

artículo científico publicado en 2009

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

artículo científico publicado en 2018

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

artículo científico publicado en 2020

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

artículo científico publicado en 2009

Role of allogeneic transplantation in multiple myeloma in the era of new drugs ⬇️

artículo científico publicado el 1 de junio de 2010

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

artículo científico publicado en 2022

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

artículo científico publicado en 2014

Standard chemotherapy for myelomatosis: an area of great controversy

artículo científico publicado el 1 de abril de 1992

Thalidomide for treatment of multiple myeloma: 10 years later

artículo científico publicado en 2008

Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments ⬇️

artículo científico publicado el 1 de marzo de 2011

Lista de obras de

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

CD3‐induced T‐cell activation in the bone marrow of myeloma patients: major role of CD4+ cells ⬇️

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.

Current multiple myeloma treatment strategies with novel agents: a European perspective

Dual rearrangement of immunoglobulin and T-cell receptor gene in a case of T-cell hairy-cell leukemia ⬇️

Early disappearance of murine plasmocytoma stem cells in long-term bone marrow culture

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

European perspective on multiple myeloma treatment strategies in 2014

European perspective on multiple myeloma treatment strategies: update following recent congresses

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

How to manage neutropenia in multiple myeloma

Insights on Multiple Myeloma Treatment Strategies

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Multiple independent immunoglobulin class-switch recombinations occurring within the same clone in myeloma

Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.

Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents

Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

Role of allogeneic transplantation in multiple myeloma in the era of new drugs ⬇️

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

Standard chemotherapy for myelomatosis: an area of great controversy

Thalidomide for treatment of multiple myeloma: 10 years later

Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments ⬇️